6-K
GSK plc (GSK)
6-K
2025-04-14
For: 2025-04-14
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Elizabeth<br>McKee Anderson | ||
| b) | Position/status | Independent<br>Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br><br>ISIN:<br>US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 10 April 2025 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $34.1210 | 26 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-11 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Charles<br>Bancroft | ||
| b) | Position/status | Senior<br>Independent Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br><br>ISIN:<br>US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 10 April 2025 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $34.1210 | 174 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-11 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Hal<br>Barron | ||
| b) | Position/status | Non-Executive<br>Director | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br><br>ISIN:<br>US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 10 April 2025 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $34.1210 | 29 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-11 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Anne<br>Beal | ||
| b) | Position/status | Independent<br>Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br><br>ISIN:<br>US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 10 April 2025 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $34.1210 | 22 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-11 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr<br>Harry Dietz | ||
| b) | Position/status | Independent<br>Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br><br>ISIN:<br>US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 10 April 2025 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $34.1210 | 22 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-11 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr<br>Jesse Goodman | ||
| b) | Position/status | Independent<br>Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br><br>ISIN:<br>US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 10 April 2025 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $34.1210 | 22 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-11 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr<br>Jeannie Lee | ||
| b) | Position/status | Independent<br>Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br><br>ISIN:<br>US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 10 April 2025 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $34.1210 | 10 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-11 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr<br>Vishal Sikka | ||
| b) | Position/status | Independent<br>Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American<br>Depositary Shares ('ADSs')<br><br><br>ISIN:<br>US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 10 April 2025 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $34.1210 | 98 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-11 | ||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Emma<br>Walmsley | ||
| b) | Position/status | Chief<br>Executive Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 4,560.318 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Diana<br>Conrad | ||
| b) | Position/status | Chief<br>People Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 1,512.439 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | James<br>Ford | ||
| b) | Position/status | SVP and<br>Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 2,662.666 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Sally<br>Jackson | ||
| b) | Position/status | SVP,<br>Global Communications and CEO Office | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 945.209 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dylan<br>Jackson | ||
| b) | Position/status | PCA<br>of Sally Jackson (SVP, Global Communications and CEO<br>Office) | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 171.965 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Luke<br>Miels | ||
| b) | Position/status | Chief<br>Commercial Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 12,698.763 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | David<br>Redfern | ||
| b) | Position/status | President<br>Corporate Development | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 7,700.043 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Regis<br>Simard | ||
| b) | Position/status | President, Global<br>Supply Chain | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 3,208.918 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Philip<br>Thomson | ||
| b) | Position/status | President,<br>Global Affairs | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 2,630.473 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Kate<br>Thomson | ||
| b) | Position/status | PCA of<br>Philip Thomson (President, Global Affairs) | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 134.156 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Deborah<br>Waterhouse | ||
| b) | Position/status | CEO,<br>ViiV Healthcare and President, Global Health, GSK | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 1,569.323 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Tony<br>Wood | ||
| b) | Position/status | Chief<br>Scientific Officer | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN:<br>GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 1,558.013 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Victoria<br>Whyte | ||
| b) | Position/status | Company<br>Secretary | ||
| c) | Initial<br>notification/amendment | Initial<br>notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK<br>plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary<br>shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition<br>of Ordinary Shares following the re-investment of dividends paid to<br>shareholders on 10 April 2025. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £13.0668 | 135.011 | |||
| d) | Aggregated<br>information | N/A<br>(single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date of<br>the transaction | 2025-04-10 | ||
| f) | Place<br>of the transaction | London<br>Stock Exchange (XLON) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: April<br>14, 2025 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |